Posts by Jason A. Efstathiou, MD, DPhil
-
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates
Douglas M. Dahl, MD, Jason A. Efstathiou, MD, DPhil, and colleagues determined that in patients with muscle-invasive bladder cancer who were not candidates for cystectomy or cisplatin, maximum tumor resection and chemoradiation were associated with high response rates and five-year overall survival rates of 25% to 38%.
-
New Research Supports Trimodality Therapy for Bladder Cancer
A new Massachusetts General Hospital study compares bladder cancer treatment options and strongly supports bladder preservation with trimodality therapy.
-
Auto-Contouring Model Performs Well for Prostate Cancer Patients Who Receive Radiopaque Hydrogel Spacer
Yi Wang, PhD, Jason A. Efstathiou, MD, DPhil, and colleagues have validated a CT-based deep learning model that provides automated contouring when planning radiation therapy for prostate cancer patients who receive the SpaceOAR Vue rectal spacer.
-
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation
Using a digital immunofluorescence assay, Jason A. Efstathiou, MD, DPhil, and colleagues showed the DNA repair protein MRE11 could guide the selection of candidates for bladder-sparing trimodality therapy for muscle-invasive bladder cancer, as higher levels were associated with 58% better cumulative four-year survival.
-
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy
Research by Massachusetts General Hospital Cancer Center oncologists suggests gene profiling of tumors from patients with muscle-invasive bladder cancer can guide rational selection of those who will benefit most from bladder-preserving trimodality therapy.
-
Comparative Effectiveness of Bladder-preserving Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer
According to decision analysis modeling by researchers at the Mass General Cancer Center, trimodality therapy with the goal of preserving the bladder is similar to radical cystectomy in terms of survival outcomes. However, trimodal therapy may provide a greater quality of life for patients with muscle-invasive bladder cancer.
-
Review: Molecular Biomarkers May Lead to Personalized Treatment of Muscle-invasive Bladder Cancer
Rapidly emerging molecular biomarkers will allow oncologists to choose more confidently between radical cystectomy and trimodality therapy for patients with muscle-invasive bladder cancer, as well as identify which patients undergoing trimodality therapy are likely to benefit from adding immunotherapy.
-
New Clues Emerge on Management of Recurrent Nonmuscle Invasive Bladder Cancer After Trimodality Therapy
When nonmuscle invasive bladder cancer develops after trimodality therapy for muscle invasive bladder cancer, salvage radical cystectomy isn't necessarily required, researchers have found.
-
Early Radiotherapy Best When Cancer Recurs After Radical Prostatectomy
The optimal timing of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy is controversial. Mass General researchers aim to clear up the controversy by reviewing patients who were treated in the modern era of PSA testing.
Biography
Dr. Efstathiou holds a B.S. from Yale University, M.D. from Harvard Medical School (HMS), Ph.D. from University of Oxford, and completed his residency training in the Harvard Radiation Oncology Program. He serves as Professor of Radiation Oncology at Harvard Medical School and Massachusetts General Hospital. His clinical practice focuses on treatment of patients with prostate, bladder, testicular and other urologic cancers, as well as proton beam and brachytherapy. He serves as vice-chair of Faculty & Academic Affairs and director of the Genitourinary Service in the Department of Radiation Oncology and clinical co-director of the Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic. His commitment to service/patient care has been recognized as honoree for the Mass General Cancer Center's "The One Hundred" and as nominee for the Brian A. McGovern Award for Clinical Excellence. His research has informed clinical practice guidelines and focuses on the effectiveness of advanced/emerging therapies for prostate cancer, including proton beam, as well as the adverse effects of hormonal therapy, improving radiation therapy for testicular cancer and long-term outcomes of bladder-sparing chemoradiation for bladder cancer. He is the recipient of significant grant funding and serves as principal investigator of multiple studies, including a multi-center randomized phase III trial of IMRT versus proton beam for localized prostate cancer using patient-reported outcomes. He lectures nationally and internationally and holds leadership positions in Radiation Oncology including within the cooperative groups (NRG), professional societies (ASTRO) and National Cancer Institute (NCI). Other projects of his include the development of web-based patient decision aids/support tools, evaluating the multidisciplinary approach to cancer care, and global oncology outreach efforts with Botswana.
Mass General Department of Radiation Oncology
The Department of Radiation Oncology combines clinical expertise, compassionate care, and advanced radiation therapies to deliver the safest, most effective treatments for cancer and benign tumors.
